ENJUVIA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ENJUVIA (ENJUVIA).

How it works

Enjuvia is a conjugated estrogen product that binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways. It increases hepatic synthesis of sex hormone-binding globulin, thyroid-binding globulin, and other proteins.

What the body does with it

Metabolism	Metabolized primarily in the liver via CYP3A4 and other enzymes; undergoes enterohepatic circulation. Major metabolites include estrone, estradiol, and their conjugates (sulfates and glucuronides).
Excretion	Renal: 70% unchanged; fecal/biliary: 30% as metabolites.
Half-life	Terminal elimination half-life: 12 hours (range 10-14 h) in healthy adults; may be prolonged in renal impairment.
Protein binding	90% bound primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.8 L/kg; indicates moderate tissue distribution and is consistent with binding to plasma proteins.
Bioavailability	Oral: 85% (range 75-95%); intravenous: 100%.
Onset of Action	Oral: 1-2 hours after administration; intravenous: within minutes.
Duration of Action	Approximately 12 hours; clinical effect persists for the dosing interval with twice-daily administration.

Classification & Brands

Dosing & administration

2 mg orally once daily

Dosage form	TABLET
Renal impairment	No adjustment required for GFR ≥30 mL/min; not recommended for GFR <30 mL/min
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: 1 mg orally once daily; Child-Pugh C: not recommended
Pediatric use	Not approved for pediatric use
Geriatric use	No specific dose adjustment; monitor for renal function due to age-related decreased GFR

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ENJUVIA (ENJUVIA).

Breastfeeding	Contraindicated during breastfeeding. ENJUVIA is excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants, including bone marrow suppression and renal toxicity.
Teratogenic Risk	Pregnancy Category X. ENJUVIA is contraindicated in pregnancy. First trimester: High risk of congenital anomalies including neural tube defects, cardiac malformations, and craniofacial defects. Second and third trimesters: Risk of fetal nephrotoxicity, oligohydramnios, and skull ossification defects.

Warnings & precautions

■ FDA Black Box Warning

Estrogens increase the risk of endometrial cancer. Do not use in women with undiagnosed abnormal genital bleeding. Estrogen-alone therapy increases the risk of stroke and deep vein thrombosis. Estrogen plus progestin therapy increases the risk of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis. Discontinue if cardiovascular event occurs.

Side Effect Profile

Serious Effects

Absolute Contraindications

Undiagnosed abnormal genital bleeding, known or suspected pregnancy, known or suspected breast cancer (except in selected advanced cases), known or suspected estrogen-dependent neoplasia, active deep vein thrombosis or pulmonary embolism, active arterial thromboembolic disease (e.g., stroke, MI), known anaphylactic reaction or angioedema to Enjuvia, liver dysfunction or disease, and known protein C, protein S, or antithrombin deficiency.

Clinical Precautions

Precautions

Cardiovascular disorders (increased risk of stroke and DVT), malignant neoplasms (endometrial cancer, breast cancer), dementia (increased risk in women ≥65 years), gallbladder disease, hypercalcemia, visual abnormalities (retinal thrombosis), fluid retention, exacerbation of hypothyroidism, and drug-induced angioedema.

Clinical Tips & Counseling

Drug interactions

Loading safety data…

ENJUVIA

Clinical safety rating: caution

Comprehensive clinical and safety monograph for ENJUVIA (ENJUVIA).

How it works

What the body does with it

Metabolism	Metabolized primarily in the liver via CYP3A4 and other enzymes; undergoes enterohepatic circulation. Major metabolites include estrone, estradiol, and their conjugates (sulfates and glucuronides).
Excretion	Renal: 70% unchanged; fecal/biliary: 30% as metabolites.
Half-life	Terminal elimination half-life: 12 hours (range 10-14 h) in healthy adults; may be prolonged in renal impairment.
Protein binding	90% bound primarily to albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.8 L/kg; indicates moderate tissue distribution and is consistent with binding to plasma proteins.
Bioavailability	Oral: 85% (range 75-95%); intravenous: 100%.
Onset of Action	Oral: 1-2 hours after administration; intravenous: within minutes.
Duration of Action	Approximately 12 hours; clinical effect persists for the dosing interval with twice-daily administration.

Classification & Brands

Dosing & administration

2 mg orally once daily

Dosage form	TABLET
Renal impairment	No adjustment required for GFR ≥30 mL/min; not recommended for GFR <30 mL/min
Liver impairment	Child-Pugh A: no adjustment; Child-Pugh B: 1 mg orally once daily; Child-Pugh C: not recommended
Pediatric use	Not approved for pediatric use
Geriatric use	No specific dose adjustment; monitor for renal function due to age-related decreased GFR

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for ENJUVIA (ENJUVIA).

Breastfeeding	Contraindicated during breastfeeding. ENJUVIA is excreted in human milk; M/P ratio not established. Potential for serious adverse reactions in nursing infants, including bone marrow suppression and renal toxicity.
Teratogenic Risk	Pregnancy Category X. ENJUVIA is contraindicated in pregnancy. First trimester: High risk of congenital anomalies including neural tube defects, cardiac malformations, and craniofacial defects. Second and third trimesters: Risk of fetal nephrotoxicity, oligohydramnios, and skull ossification defects.